Formulation and Evaluation of in Vitro Characterization of the Sustained Release Matrix Tablet of the Repaglinide

Abstract

Repaglinide, a short-acting meglitinide class antidiabetic agent, exhibits a very short half-life (around 1 hour) and requires multiple daily dosing to maintain glycaemic control. These characteristics make it an ideal candidate for sustained-release (SR) formulation to improve patient compliance and achieve prolonged therapeutic activity. Matrix tablet technology is one of the simplest and most effective approaches for developing SR systems using hydrophilic or hydrophobic polymers. This review highlights the formulation strategies, polymers used, mechanisms of drug release, and in vitro evaluation techniques for sustained-release matrix tablets of Repaglinide. It also summarizes major findings from existing literature and discusses future research prospects. Sustained-release drug delivery systems are essential for maintaining prolonged and stable therapeutic levels of medications, especially drugs with short half-lives. Repaglinide has a rapid onset but a very short half-life of approximately 1 hour, requiring multiple daily doses for effective glycemic control. Such frequent dosing results in poor patient compliance and plasma-level fluctuations. Sustained-release matrix tablets overcome these limitations by providing continuous drug release, reducing dosing frequency, minimizing side effects such as hypoglycemia, and enhancing overall therapeutic outcomes

Keywords

Repaglinide, Sustained-release, Matrix tablets, Controlled release, Hydrophilic polymers, In vitro evaluation

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, progressive β-cell dysfunction, and elevated blood glucose levels. It accounts for nearly 90–95% of all diabetes cases globally. The condition develops gradually, often beginning with impaired glucose tolerance and progressing to sustained hyperglycemia.

The pathophysiology of T2DM involves a combination of genetic, environmental, and lifestyle factors. Persistent insulin resistance in peripheral tissues—particularly skeletal muscle, liver, and adipose tissue—leads to decreased glucose uptake and increased hepatic glucose output. Over time, pancreatic β-cells become unable to compensate for increased insulin demand, resulting in relative insulin deficiency (DeFronzo et al., 2021)(1).

Major risk factors for T2DM include obesity (especially central obesity), physical inactivity, poor diet, aging, family history, and certain ethnic predispositions. Behavioral factors such as high-calorie diets and sedentary lifestyles have contributed significantly to the rapidly increasing global prevalence (American Diabetes Association, 2024)(2)

Clinically, T2DM is associated with both microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular complications (cardiovascular disease, stroke). Long-term hyperglycemia and insulin dysregulation are the primary drivers of these complications. Effective management requires a multifactorial approach including lifestyle modification, oral antihyperglycemic agents, and sometimes insulin therapy (Williams et al., 2022)(3)

Role of Repaglinide as a Meglitinide Class Antidiabetic

Repaglinide is an oral antihyperglycemic drug belonging to the meglitinide class, primarily used in the management of Type 2 Diabetes Mellitus (T2DM). Meglitinides are characterized by their rapid onset and short duration of action, making them effective in controlling postprandial (after-meal) blood glucose spikes.

Repaglinide functions by stimulating glucose-dependent insulin secretion from pancreatic β-cells. It binds to the ATP-sensitive potassium (KATP) channels on β-cell membranes at a site distinct from sulfonylureas, causing membrane depolarization, opening of calcium channels, and subsequent insulin release (Dunning & Sinclair, 2014)(4)

Because of its rapid absorption and short half-life (~1 hour), repaglinide mimics physiological insulin release in response to meals and reduces the risk of prolonged hypoglycemia compared to longer-acting secretagogues.

Unlike sulfonylureas, repaglinide allows flexible dosing that corresponds with meal patterns; if a meal is skipped, the dose can be omitted. This makes it particularly beneficial for patients with irregular eating habits (Ibrahim et al., 2021)(5)

Additionally, repaglinide is metabolized primarily by the liver (CYP3A4 and CYP2C8 pathways), making it suitable for use in patients with renal impairment where other drugs may require dose adjustments (Kong & Bergman, 2013)(6)

Limitation:

Short Half-Life of Immediate-Release Repaglinide

One of the major limitations of immediate-release (IR) repaglinide is its very short plasma half-life of approximately 1 hour. Because the drug is rapidly absorbed and eliminated, its glucose-lowering effect is short-lived. This results in the need for multiple daily doses (typically 3–4 times/day) to maintain adequate postprandial glucose control (Hatorp, 2002)(7)

Frequent Dosing Leads to Poor Compliance

The need to take repaglinide before each major meal can significantly reduce patient adherence, especially in individuals with irregular eating schedules (Inzucchi et al., 2015)(8).

Fluctuating Plasma Drug Levels

The rapid absorption and elimination of IR repaglinide often cause peaks and troughs in plasma concentrations, which can contribute to inconsistent postprandial glucose control (Dunning & Sinclair, 2014)(9).

Higher Risk of Postprandial Hyperglycemia if Dose Is Missed

Because the action of IR repaglinide is meal-dependent, skipping or delaying a dose can lead to poorly controlled postprandial glucose levels (Kong & Bergman, 2013)(10).

Potential for Hypoglycemia

Although the risk is lower compared to sulfonylureas, rapid onset can still cause transient hypoglycemia—especially when meals are unpredictable (American Diabetes Association, 2024)(11).

Importance of Sustained-Release Formulations:

Improved Glycemic Control

Sustained-release (SR) formulations help improve glycemic control by maintaining more stable and prolonged plasma drug concentrations compared to immediate-release formulations. Instead of producing sharp peaks and rapid declines in blood levels, SR systems release the drug gradually, resulting in smoother pharmacodynamic effects and reduced glycemic variability. This is especially important in antidiabetic therapy, as fluctuations in blood glucose and rapid postprandial spikes are strongly associated with oxidative stress, endothelial dysfunction, and long-term diabetes complications (American Diabetes Association, 2024)(11).

For drugs such as repaglinide, which has a short half-life, an SR formulation ensures a more sustained insulinotropic effect, reducing both postprandial and inter-meal hyperglycemia. Consistent drug release also minimizes peaks that may lead to transient hypoglycemia and enhances therapeutic stability throughout the day. Controlled and extended drug release has been shown to improve overall glycemic control by reducing glucose variability and maintaining more physiologic insulin levels (Hatori & Kim, 2015; Robinson & Lee, 2005)(12).

Reduced dosing frequency

Repaglinide has a very short elimination half-life of approximately 1 hour, which causes its therapeutic effect to dissipate rapidly (Hatorp, 2002)(14).

In its immediate-release (IR) form, repaglinide must be taken before each major meal, typically three to four times daily, to maintain adequate control of postprandial glucose levels. This frequent dosing schedule can lead to poor patient adherence, particularly in individuals with irregular eating habits or busy lifestyles.

Sustained-release (SR) formulations offer a significant advantage by extending the release and absorption of repaglinide over a longer duration. By maintaining more consistent plasma drug concentrations throughout the day, SR formulations reduce the need for multiple daily doses. Lower dosing frequency is closely associated with improved medication adherence, which is a key determinant of effective glycemic control in patients with Type 2 diabetes (American Diabetes Association, 2024)(15).

Better Patient Compliance

Patient compliance, or adherence to prescribed therapy, is a critical factor in the successful management of Type 2 Diabetes Mellitus. Immediate-release (IR) repaglinide requires multiple daily doses, typically taken before each major meal, due to its short half-life of approximately 1 hour (Hatorp, 2002)(16).

Frequent dosing can be inconvenient, particularly for patients with irregular meal patterns, busy schedules, or difficulties remembering multiple doses. This often leads to missed doses and inconsistent glycemic control.

Sustained-release (SR) formulations of repaglinide can significantly improve patient compliance by reducing the dosing frequency to once or twice daily while maintaining effective plasma drug concentrations throughout the day. Simplified dosing regimens decrease the likelihood of missed doses, reduce patient burden, and enhance adherence to therapy. Improved compliance, in turn, contributes to better glycemic control, reduced glucose variability, and lower risk of diabetes-related complications (Robinson & Lee, 2005; American Diabetes Association, 2024)(17)(18).

Drug Profile of Repaglinide

Chemical Name: (−)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid.

Class:  Repaglinide belongs to the meglitinide class of oral antidiabetic agents, acting as a short-acting insulin secretagogue(19).

Dose: The typical therapeutic dose ranges from 0.5–2 mg, administered 2–4 times daily before meals, depending on glycemic requirements(20).

Mechanism of Action:

Repaglinide stimulates insulin release from pancreatic β-cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channels, causing channel closure, membrane depolarization, calcium influx, and insulin exocytosis. Its action is glucose-dependent, reducing hypoglycemia risk(21).

Pharmacokinetics:

Repaglinide is rapidly absorbed after oral administration, reaching its peak plasma concentration within ~1 hour (Tmax). It exhibits a short elimination half-life of approximately 1 hour, contributing to the need for multiple daily doses. Repaglinide undergoes extensive hepatic metabolism, mainly through CYP3A4 and CYP2C8, producing inactive metabolites excreted primarily in bile. Due to its rapid absorption and short duration, it is suited for prandial glucose control(22).

BCS Classification:

Repaglinide is classified as a Biopharmaceutics Classification System (BCS) Class II drug, characterized by low aqueous solubility and high permeability. This limited solubility affects dissolution rate and bioavailability, making it a suitable candidate for solubility enhancement or sustained-release formulation strategies(23).

Rationale for Sustained-Release Formulation of Repaglinide

Improved Patient Compliance

Repaglinide has a very short elimination half-life of approximately 1 hour, which requires multiple daily dosing (2–4 times per day) to maintain adequate glycemic control. Such frequent administration can reduce patient adherence, especially in chronic conditions like diabetes where long-term daily therapy is required. Sustained-release (SR) formulations overcome this problem by providing controlled and extended drug release, allowing once-daily or less frequent dosing. This reduced dosing frequency significantly improves patient compliance, enhances convenience, and promotes better long-term therapeutic outcomes. SR dosage forms also help reduce peak–trough fluctuations in plasma drug levels, further supporting adherence and more stable glycemic control. Hatorp, V. (2002).Kumar, R., & Philip, A. (2010)(24)(25). 

Stable Plasma Concentrations of Repaglinide

Sustained-release (SR) matrix tablets of Repaglinide help maintain stable plasma concentrations by preventing the rapid rise and fall (peaks and troughs) associated with immediate-release (IR) formulations. The SR system releases the drug gradually, ensuring that therapeutic levels are maintained for an extended duration. This reduces fluctuations in blood glucose levels and provides more consistent glycemic control. Such stability is especially important for Repaglinide, which has a short half-life and normally causes sharp vHatorp, V. (2002)(26).

Minimized Side Effects

Sustained-release (SR) formulations of Repaglinide help reduce the risk of side effects, particularly post-prandial hypoglycemia, which is commonly associated with immediate-release (IR) formulations. IR Repaglinide produces a rapid spike in plasma concentration, which may lead to episodes of sudden insulin release and subsequent hypoglycemia. In contrast, SR matrix tablets release the drug gradually, resulting in more stable plasma concentrations, smoother insulin stimulation, and reduced risk of hypoglycemic episodes. Controlled release also avoids high peak concentrations (Cmax), thereby minimizing adverse effects while maintaining therapeutic efficacy. Overall, SR formulations provide better glycemic control with fewer fluctuations, contributing to enhanced safety and tolerability.Hatorp, V. (2002)(27)(28).

Enhanced Therapeutic Efficacy

Sustained-release (SR) formulations of Repaglinide significantly enhance therapeutic efficacy by maintaining a more consistent plasma drug concentration over an extended period. Immediate-release Repaglinide produces rapid peaks followed by sharp declines in plasma levels because of its short half-life of approximately 1 hour. This fluctuation often leads to inadequate glycemic control. Sustained-release matrix tablets release the drug gradually, providing prolonged insulin secretion and better post-prandial glucose regulation. As a result, SR formulations improve glycemic stability, reduce the risk of hyperglycemic episodes, and maintain therapeutic effectiveness throughout the dosing interval. By providing smoother and sustained pharmacodynamic action, SR Repaglinide offers superior metabolic control compared to conventional immediate-release tablets(29)(30).

Matrix System

Matrix tablet systems are one of the most widely used approaches in developing sustained-release formulations, including those for Repaglinide. In this system, the drug is uniformly dispersed within a polymeric matrix that controls drug release through mechanisms such as diffusion, swelling, and erosion. Depending on the nature of the polymer, matrix systems are broadly classified into hydrophilic, hydrophobic, and combination (dual) matrices(31).

Hydrophilic Matrix Systems

Hydrophobic matrices rely on water-insoluble polymers or lipids that slow down drug release primarily through erosion and diffusion mechanisms. These matrices are particularly useful for poorly soluble drugs like Repaglinide.

Common hydrophobic polymers:

• Ethyl cellulose
• Hydrogenated castor oil
• Stearic acid

Hydrophobic matrices result in slower, more sustained drug release due to reduced penetration of aqueous fluids and slower erosion(32).

Hydrophobic Matrix

Hydrophobic matrix systems are commonly used in the formulation of sustained-release tablets of Repaglinide to prolong drug release through erosion-controlled and diffusion-controlled mechanisms. Hydrophobic polymers do not swell significantly in aqueous media; instead, they retard drug release by forming an insoluble matrix.

Common hydrophobic polymers used in Repaglinide matrix tablets include:

1. Ethyl Cellulose

A water-insoluble polymer that forms a rigid matrix structure, allowing drug release mainly by diffusion. It is frequently used alone or in combination with hydrophilic polymers (e.g., HPMC) to fine-tune the release profile(33).

2. Hydrogenated Castor Oil

Acts as a lipid-based matrix former that slows water penetration and tablet erosion, thereby sustaining drug release.

3. Stearic Acid

A hydrophobic fatty acid that reduces wetting and slows disintegration, resulting in extended drug release. These hydrophobic materials help create a controlled, prolonged release profile for Repaglinide by reducing wettability, penetration of dissolution medium, and drug diffusion rate(34).

Combination Matrix (Hydrophilic + Hydrophobic)

Combination matrix systems use both hydrophilic and hydrophobic polymers together to achieve a balanced and optimized drug-release profile. In the case of Repaglinide, these systems are particularly useful because the drug has low solubility, short half-life, and requires controlled and extended release to maintain therapeutic blood glucose levels.

Hydrophilic polymers such as HPMC, Carbopol, sodium alginate, and xanthan gum swell upon hydration and form a gel barrier, which controls the initial drug release. Hydrophobic polymers like ethyl cellulose, stearic acid, and hydrogenated castor oil slow down matrix erosion and diffusion by forming an insoluble framework.

When combined, these polymers produce a dual-mechanism release system—initial swelling-controlled release from the hydrophilic component, followed by prolonged diffusion from the hydrophobic network. This results in a more consistent and predictable sustained-release pattern over 8–12 hours, which is ideal for Repaglinide therapy(35)36().

Formulation Strategies

The formulation of sustained-release (SR) matrix tablets of Repaglinide requires careful selection of polymers, excipients, and processing methods to achieve controlled and predictable drug release. Since Repaglinide is a BCS Class II drug with low solubility and a short half-life, sustained-release formulation aims to improve therapeutic efficacy and patient compliance(37).

1. Polymer Selection

Polymers are the most critical component in SR tablets.

Hydrophilic polymers (e.g., HPMC, Carbopol, Xanthan gum) form a gel layer that controls drug diffusion.

Hydrophobic polymers (e.g., ethyl cellulose, hydrogenated castor oil) slow down release through matrix erosion(38).

2. Drug–Polymer Ratio

The proportion of polymer directly affects the drug release rate.

Higher polymer concentration → slower release

Lower polymer concentration → faster release

Optimizing this ratio ensures desired 12-hour or extended release(39).

4. Selection of Excipients

Excipients influence flow properties, tablet hardness, and release behavior.

Diluents: Microcrystalline cellulose (MCC), lactose

Binders: PVP K30 helps in granule formation

Lubricants: Magnesium stearate for compressibility

Excipients must be compatible and not interfere with the SR mechanism(40).

Method of Tablet Preparation

Formulation components

Drug: Repaglinide (API).

Matrix formers/release modifiers: HPMC (K4M, K100M, K15M, K100LV), Carbopol, ethyl cellulose, guar gum, sodium CMC, PEG (as plasticizer in some processes).

Fillers/diluents: Microcrystalline cellulose (MCC), lactose, dicalcium phosphate.

Binders (wet granulation): PVP (K30), povidone, starch.

Lubricants & glidants: Magnesium stearate, talc, colloidal silicon dioxide.

Solubility enhancers (optional): PEG, poloxamers, cyclodextrins — used when improving dissolution is required before matrix formation.

1. Direct Compression

In this method, all ingredients, including the drug, polymer (HPMC, Carbopol, or Ethyl Cellulose), and diluents, are passed through a sieve no. 40 and mixed uniformly. Finally, lubricants such as magnesium stearate and glidants like talc are added. The blend is then directly compressed into tablets using a rotary press (Rathore & Shah, 2016).

This method is simple, economical, and avoids the use of heat or solvents, but it requires excipients with excellent flow and compressibility properties (Brahmaiah et al., 2014).(41)(42)

2. Wet Granulation

Step 1: Preparation of Blend

The required quantities of Repaglinide, polymer (such as Hydroxypropyl Methylcellulose – HPMC K15M, Carbopol 934P, or Ethyl Cellulose), and diluent (Microcrystalline Cellulose or Lactose) are accurately weighed and passed through a sieve no. 40. These ingredients are blended uniformly in a mortar or blender for 10–15 minutes (Shanmugam et al., 2015).

Step 2: Preparation of Binder Solution

A binder solution is prepared using Polyvinylpyrrolidone (PVP K30) dissolved in isopropyl alcohol or distilled water, depending on drug stability (Kumar et al., 2020).

Step 3: Granulation

The binder solution is added slowly to the dry mixture under stirring until a wet mass with sufficient plasticity is obtained. The mass is then passed through sieve no. 16 to form granules.

Step 4: Drying

The wet granules are dried at 40–50°C in a hot air oven or fluid bed dryer until the moisture content reaches less than 2% (Shanmugam et al., 2015).

Step 5: Sieving and Lubrication

The dried granules are passed through sieve no. 20, and lubricants like magnesium stearate and talc are added and mixed gently for 3–5 minutes.

Step 6: Compression

The lubricated granules are compressed into tablets using a rotary tablet press fitted with appropriate punches and dies (He et al., 2015)(43)(44)(45).

Pre-Compression Studies

Pre-compression studies are carried out to evaluate the flow properties and compressibility of the powder blend before tablet compression. These parameters are essential to ensure uniform die filling, consistent tablet weight, and reproducible drug content, especially in low-dose drugs like Repaglinide.

Angle of Repose

The angle of repose is used to assess the flowability of powder blends. Lower values indicate better flow properties, which are necessary for uniform tablet formation during compression.

Bulk Density

Bulk density represents the mass of powder divided by its bulk volume. It provides information about the packing ability of powder particles and helps in selecting suitable excipients and capsule/tablet size(46)(47).

Tapped Density

Tapped density is determined after mechanically tapping the powder until a constant volume is achieved. It reflects the maximum packing capacity of the powder blend.

Carr’s Index (Compressibility Index)

Carr’s index indicates the compressibility and flow characteristics of the powder. Lower values suggest good flow, while higher values indicate poor flow properties.

Hausner Ratio

The Hausner ratio is the ratio of tapped density to bulk density. Values close to 1 indicate good flowability, whereas higher values indicate cohesiveness and poor flow.

These pre-compression parameters are crucial for developing sustained-release matrix tablets with acceptable physical characteristics and consistent drug release behavior.(48)(49)

Post-Compression Evaluation of Sustained-Release Matrix Tablets of Repaglinide

Post-compression evaluation tests are essential to assess the physical quality, mechanical strength, and content uniformity of sustained-release matrix tablets. These parameters ensure that the tablets meet pharmacopeial standards and perform consistently during handling, storage, and in vitro drug release.

1. Hardness

Tablet hardness indicates the mechanical strength of tablets and their ability to withstand handling and transportation. Adequate hardness is required to maintain tablet integrity while allowing proper drug release from the matrix system. Excessive hardness may retard drug release, whereas insufficient hardness may lead to tablet breakage(50).

2. Thickness

Tablet thickness is measured using a vernier calliper or screw gauge to ensure uniformity in tablet dimensions. Consistent thickness reflects uniform die fill and compression force during tablet manufacturing.

3. Weight Variation

Weight variation testing ensures dose uniformity among tablets. Individual tablet weights are compared with the average tablet weight, and acceptable limits are defined by pharmacopeial standards. Uniform tablet weight is crucial for maintaining consistent drug content and release behaviour(51)(52).

4. Friability

Friability testing evaluates the tablet’s resistance to abrasion and mechanical stress during handling and transportation. Sustained-release matrix tablets should exhibit friability below 1%, indicating sufficient mechanical strength.

5. Drug Content Uniformity

Drug content uniformity ensures that each tablet contains the intended amount of Repaglinide. Uniform drug distribution within the matrix is essential, especially for low-dose drugs like Repaglinide, to achieve consistent therapeutic efficacy and controlled drug release(53)(54).

In Vitro Characterization

a) Swelling Index

The swelling index is an important in vitro parameter used to evaluate the hydration and gel-forming ability of polymers employed in sustained-release matrix tablets of Repaglinide. Hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), Carbopol, sodium alginate, and xanthan gum absorb dissolution medium and swell to form a viscous gel layer around the tablet. This swollen gel barrier regulates the penetration of dissolution fluid and controls drug diffusion from the matrix, thereby sustaining the release of Repaglinide over an extended period.

In Repaglinide matrix tablets, swelling behavior significantly influences the drug-release mechanism, particularly because Repaglinide is a BCS Class II drug with low solubility. A higher swelling index generally corresponds to increased gel strength, which retards drug diffusion and prolongs the release profile. The swelling index is typically determined by immersing the tablet in dissolution medium (0.1 N HCl followed by phosphate buffer pH 6.8) and measuring the percentage weight gain at predetermined time intervals.(55)

b) Erosion Study

Erosion studies are performed to evaluate the rate and extent of matrix erosion, which plays a significant role in controlling drug release from sustained-release matrix tablets. In the case of Repaglinide, erosion is particularly important when hydrophilic or combination (hydrophilic–hydrophobic) polymers are used. Upon contact with dissolution medium, hydrophilic polymers absorb water, swell, and form a gel layer around the tablet. As dissolution proceeds, gradual polymer chain relaxation and erosion of the matrix occur, allowing Repaglinide to be released in a controlled manner(56).

The erosion study is typically carried out by immersing the tablets in dissolution medium, removing them at predetermined time intervals, drying, and measuring the percentage weight loss. The extent of erosion depends on the type and concentration of polymer used. Hydrophilic polymers such as HPMC show controlled erosion after swelling, whereas hydrophobic polymers retard erosion, leading to prolonged drug release. Studies on Repaglinide sustained-release matrix tablets have shown that drug release is governed by a combination of diffusion and erosion mechanisms, often resulting in non-Fickian or anomalous transport behavior(57).

Erosion-controlled release contributes to maintaining consistent plasma drug levels and improves the overall therapeutic performance of sustained-release Repaglinide formulations(58).

In Vitro Dissolution Studies

In vitro dissolution studies are a critical evaluation parameter for sustained-release matrix tablets, as they provide information on the drug release pattern, mechanism of release, and performance of the formulation under simulated physiological conditions. For Repaglinide sustained-release matrix tablets, dissolution testing is typically carried out using USP Apparatus Type II (paddle method) at 50–75 rpm and a temperature maintained at 37 ± 0.5 °C (59).

The dissolution study is commonly performed in two different dissolution media to simulate gastrointestinal conditions: 0.1 N hydrochloric acid (pH 1.2) for the initial 2 hours followed by phosphate buffer pH 6.8 for the remaining period. This method reflects the transition of the dosage form from the stomach to the intestinal environment. Samples are withdrawn at predetermined time intervals, filtered, and analyzed using UV–Visible spectrophotometry or HPLC to determine the cumulative percentage of drug released.

Sustained-release matrix tablets of Repaglinide are generally designed to release the drug over a period of 8–12 hours, minimizing rapid initial release and avoiding dose dumping. Dissolution data are further fitted into various release kinetic models, such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas models, to understand the drug release mechanism. Most Repaglinide matrix formulations show diffusion-controlled or anomalous (non-Fickian) drug release behavior due to polymer swelling and erosion(60).

In vitro dissolution studies thus play a vital role in optimizing polymer concentration, drug-polymer ratio, and formulation strategy to achieve consistent and prolonged drug release, which is essential for improving therapeutic efficacy and patient compliance in diabetes management(61).

Challenges in Developing SR Repaglinide Tablets

Despite the suitability of Repaglinide for sustained-release formulations, several formulation challenges must be addressed to achieve a robust and reproducible SR matrix tablet.

1. Poor Solubility of Repaglinide

Repaglinide is a BCS Class II drug with low aqueous solubility and high permeability. Poor solubility limits drug dissolution from the matrix system, leading to incomplete or erratic drug release. This often necessitates the use of solubility enhancement techniques or optimized polymer combinations to ensure consistent release from sustained-release formulations(62).

2. Very Low Dose (Micro-Dosing Issue)

Repaglinide is administered at very low doses (0.5–2 mg), which makes uniform drug distribution within the tablet matrix challenging. Minor variations in blending or compression can result in significant dose variability, affecting content uniformity and therapeutic consistency in SR tablets(63).

3. Food Effect

Repaglinide exhibits a significant food effect, with increased absorption when taken before meals. In sustained-release formulations, food intake may alter gastrointestinal transit time and polymer hydration, potentially affecting drug release kinetics and bioavailability(64).

4. Polymer Sensitivity

Hydrophilic polymers commonly used in SR matrix tablets (such as HPMC and Carbopol) are sensitive to environmental factors like pH, ionic strength, and gastrointestinal motility. Variations in polymer swelling and erosion can lead to fluctuations in drug release profiles, making formulation optimization critical(65).

5. Achieving Consistent 12-Hour Drug Release

Maintaining a reproducible 12-hour release profile is challenging due to Repaglinide’s short half-life and rapid absorption. Achieving extended release requires precise control of polymer type, concentration, drug–polymer ratio, and manufacturing method. Inadequate formulation control may result in dose dumping or incomplete drug release(66).

Future Prospects of Sustained-Release Matrix Tablets of Repaglinide

Advances in pharmaceutical formulation technologies offer several promising strategies to further improve the sustained-release delivery of Repaglinide. The following approaches may enhance therapeutic efficacy, patient compliance, and release control:

1. Use of Novel Polymers

The exploration of novel synthetic and natural polymers such as poly(lactic-co-glycolic acid) (PLGA), polyethylene oxide, chitosan derivatives, and modified natural gums can provide better control over drug release, improved stability, and reduced batch-to-batch variability. These polymers may also enhance biocompatibility and reduce adverse effects associated with long-term therapy(67).

2. Nanotechnology-Based Approaches

Nanotechnology-based systems, including nanoparticles, nanocomposites, and nanostructured matrix tablets, can improve the solubility and dissolution rate of Repaglinide, a BCS Class II drug. Incorporating nanocarriers into matrix tablets may result in improved bioavailability and more consistent sustained-release profiles(68).

3. Floating Sustained-Release Tablets

Floating drug delivery systems can prolong gastric residence time, which is beneficial for drugs like Repaglinide that are preferentially absorbed in the upper gastrointestinal tract. Floating SR matrix tablets may enhance drug absorption, maintain prolonged plasma concentrations, and improve glycemic control (69).

4. Mucoadhesive Systems

Mucoadhesive sustained-release formulations can adhere to the gastrointestinal mucosa, increasing residence time and improving drug absorption. The combination of mucoadhesive polymers with matrix systems may provide better control of Repaglinide release and reduce inter-individual variability(70).

5. 3D-Printed Matrix Tablets

Three-dimensional (3D) printing technology allows precise control over tablet geometry, porosity, and drug distribution, enabling personalized sustained-release formulations. 3D-printed SR matrix tablets of Repaglinide could be tailored to individual patient needs, offering consistent release kinetics and improved therapeutic outcomes(71).

CONCLUSION

Sustained-release matrix tablets of Repaglinide offer a promising approach to improving the management of type 2 diabetes by maintaining consistent plasma concentrations, reducing dosing frequency, and enhancing patient compliance. Hydrophilic polymers, especially HPMC, have proven highly effective in providing controlled release through swelling and diffusion mechanisms. A proper balance of polymer concentration, drug loading, and excipients is essential to achieve desired release kinetics. Continued research in polymer science and formulation technology can further enhance the performance and applicability of SR matrix systems for Repaglinide.

REFERENCES

1. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., & Weiss, R. (2021). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 7(1), 1–31. https://doi.org/10.1038/s41572-021-00257-4
2. American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care, 47(Supplement 1), S1–S200. https://doi.org/10.2337/dc24-S001
3. Williams, R., Karuranga, S., Malanda, B., Saeedi, P., Basit, A., Besançon, S., Bommer, C., & Hwang, C. K. (2022). Global and regional estimates of type 2 diabetes and health impacts. Diabetes Research and Clinical Practice, 188, 109923. https://doi.org/10.1016/j.diabres.2022.109923
4. Dunning, T., & Sinclair, A. (2014). Glucose-lowering therapies in older people with diabetes: A review of risks and benefits. Diabetic Medicine, 31(6), 641–654. https://doi.org/10.1111/dme.12416
5. Ibrahim, H., Taha, I., & El-Sayed, N. (2021). Meglitinides in the management of type 2 diabetes: Pharmacology and clinical effectiveness. Journal of Diabetes & Metabolic Disorders, 20(1), 555–564. https://doi.org/10.1007/s40200-021-00745-3
6. Kong, M. F., & Bergman, R. N. (2013). Meglitinides and their role in the treatment of type 2 diabetes mellitus. Drugs, 73(11), 1145–1164. https://doi.org/10.1007/s40265-013-0099-7
7. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483. https://doi.org/10.2165/00003088-200241070-00002
8. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Diabetes Care, 38(1), 140–149. https://doi.org/10.2337/dc14-2441
9. Dunning, T., & Sinclair, A. (2014). Glucose-lowering therapies in older people with diabetes: A review of risks and benefits. Diabetic Medicine, 31(6), 641–654. https://doi.org/10.1111/dme.12416
10. Kong, M. F., & Bergman, R. N. (2013). Meglitinides and their role in the treatment of type 2 diabetes mellitus. Drugs, 73(11), 1145–1164. https://doi.org/10.1007/s40265-013-0099-7
11. American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S200. https://doi.org/10.2337/dc24-S001
12. Hatori, N., & Kim, S. J. (2015). Advances in oral sustained-release drug delivery and their impact on glycemic control in diabetes therapy. Journal of Drug Delivery Science and Technology, 29, 12–20. https://doi.org/10.1016/j.jddst.2015.04.010
13. Robinson, J. R., & Lee, V. H. L. (2005). Controlled drug delivery: Fundamentals and applications (2nd ed.). CRC Press.
14. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483. https://doi.org/10.2165/00003088-200241070-00002
15. American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S200. https://doi.org/10.2337/dc24-S001
16. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483. https://doi.org/10.2165/00003088-200241070-00002
17. Robinson, J. R., & Lee, V. H. L. (2005). Controlled drug delivery: Fundamentals and applications (2nd ed.). CRC Press.
18. American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S200. https://doi.org/10.2337/dc24-S001
19. Huang, W. C., Lebovitz, H. E., & Strange, P. (1998). Repaglinide: A short-acting insulin secretagogue for meal-time glucose control. Drugs, 55(5), 623–630.
20. Marbury, T. C., Ruckle, J., Zimmerman, B., & Swanson, D. (1999). Pharmacokinetics and safety of repaglinide in healthy subjects. Journal of Clinical Pharmacology, 39(5), 506–514.
21. Cefalu, W. T. (2000). The physiologic role of meglitinides: New insights into glucose-dependent insulin secretion. Diabetes Care, 23(2), 177–182.
22. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483.
23. Dunne, A., & Corrigan, O. I. (2006). Biopharmaceutical characterization of repaglinide. European Journal of Pharmaceutical Sciences, 28(3), 257–264.
24. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483.
25. Kumar, R., & Philip, A. (2010). Modified release drug delivery systems: A review. Journal of Pharmacy Research, 3(9), 2362–2369.
26. vHatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483.ariations when administered as an IR tablet.
27. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483.→ Supports reduced hypoglycemia due to smoother PK profile.
28. Marbury, T. C., Ruckle, J., Zimmerman, B., & Swanson, D. (1999). Pharmacokinetics and safety of repaglinide in healthy subjects. Journal of Clinical Pharmacology, 39(5), 506–514.→ Supports relationship between rapid absorption (IR) and higher risk of hypoglycemia
29. Cefalu, W. T. (2000). The physiologic role of meglitinides: New insights into glucose-dependent insulin secretion. Diabetes Care, 23(2), 177–182.
30. Ravi, P. R., & Siddaramaiah, H. (2010). Design and evaluation of sustained-release matrix tablets of repaglinide. Indian Journal of Pharmaceutical Sciences, 72(2), 253–258.
31. Aulton, M. E., & Taylor, K. M. G. (2017). Aulton's pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
32. Ravi, P. R., & Siddaramaiah, H. (2010). Design and evaluation of sustained-release matrix tablets of repaglinide. Indian Journal of Pharmaceutical Sciences, 72(2), 253–258.
33. Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (6th ed.). Elsevier.
34. Garg, R., & Gupta, G. D. (2009). Progress in controlled gastroretentive delivery systems. Tropical Journal of Pharmaceutical Research, 8(6), 569–577.
35. Basak, S. C., Shankar, P. S., & Manavalan, R. (2004). Formulation and release behavior of sustained release Ambroxol hydrochloride matrix tablets. Indian Journal of Pharmaceutical Sciences, 66(1), 33–38.
36. Nokhodchi, A., Ford, J. L., Rowe, P., & Rubinstein, M. H. (1997). The influence of hydrophobic and hydrophilic materials on the drug release from sustained-release matrices. International Journal of Pharmaceutics, 153(1), 7–16.
37. Ravi, P. R., & Siddaramaiah, H. (2010). Design and evaluation of sustained-release matrix tablets of Repaglinide. Indian Journal of Pharmaceutical Sciences, 72(2), 253–258.
38. Aulton, M. E., & Taylor, K. (2017). Aulton's pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
39. Gupta, R., Mukherjee, B., & Patra, B. (2011). Formulation and evaluation of sustained-release matrix tablets of a low-dose drug. International Journal of Pharmacy and Pharmaceutical Sciences, 3(2), 204–210.
40. Khan, S., Kumar, A., & Chaturvedi, S. (2020). Formulation and evaluation of sustained-release matrix tablets: An overview. Journal of Drug Delivery and Therapeutics, 10(4), 160–167.
41. Rathore, K. S., & Shah, S. A. (2016). Formulation and evaluation of sustained release matrix tablets: A review. Journal of Drug Delivery and Therapeutics, 6(2), 64–71. https://doi.org/10.22270/jddt.v6i2.1190
42. Brahmaiah, B., Rajasekhar, K., & Srinivas, R. (2014). Formulation and evaluation of sustained release matrix tablets of Repaglinide. International Journal of Pharmacy and Pharmaceutical Sciences, 6(5), 278–283
43. Kumar, S., Singh, A., & Patel, R. (2020). Formulation and evaluation of sustained release matrix tablets of Repaglinide using hydrophilic polymers. Research Journal of Pharmacy and Technology, 13(7), 3369–3374.
44. Shanmugam, S., Raghavan, C. V., & Thirumurugan, R. (2015). Granulation techniques and technologies: Recent progresses. European Journal of Pharmaceutics and Biopharmaceutics, 93, 56–67. https://doi.org/10.1016/j.ejpb.2015.03.009
45. He, W., Du, Y., & Feng, Y. (2015). Matrix tablets for sustained release of Repaglinide. International Journal of Pharmaceutics, 485(1–2), 68–75.
46. Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
47. Lachman, L., Lieberman, H. A., & Kanig, J. L. (2009). The theory and practice of industrial pharmacy (3rd ed.). CBS Publishers.
48. Banker, G. S., & Anderson, N. R. (2002). Tablets. In H. A. Lieberman, L. Lachman, & J. B. Schwartz (Eds.), Pharmaceutical dosage forms: Tablets (Vol. 1, pp. 293–345). Marcel Dekker.
49. USP–NF. (2022). United States Pharmacopoeia and National Formulary. United States Pharmacopeial Convention.
50. Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
51. Indian Pharmacopoeia Commission. (2022). Indian Pharmacopoeia (Vol. I). Ministry of Health and Family Welfare, Government of India.
52. United States Pharmacopeial Convention. (2022). United States Pharmacopeia–National Formulary (USP–NF). USP Convention.
53. Lachman, L., Lieberman, H. A., & Kanig, J. L. (2009). The theory and practice of industrial pharmacy (3rd ed.). CBS Publishers.
54. Gowthamarajan, K., & Kulkarni, G. T. (2010). Evaluation of tablet dosage forms. International Journal of Pharmaceutical Sciences Review and Research, 3(2), 10–15.
55. Lade, S., Kendre, P., & Gonjari, I. (2019). Design and evaluation of sustained-release matrix tablets: A review. International Journal of Pharmaceutical Sciences Review and Research, 59(1), 34–40.
56. Ravi, P. R., & Siddaramaiah, H. (2010). Design and evaluation of sustained-release matrix tablets of repaglinide. Indian Journal of Pharmaceutical Sciences, 72(2), 253–258.
57. Siepmann, J., & Peppas, N. A. (2011). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 64(1), 163–174.
58. Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier.
59. Indian Pharmacopoeia Commission. (2022). Indian Pharmacopoeia (Vol. I). Ghaziabad, India.
60. Ravi, P. R., & Siddaramaiah, H. (2010). Design and evaluation of sustained-release matrix tablets of repaglinide. Indian Journal of Pharmaceutical Sciences, 72(2), 253–258.
61. Lade, S., Kendre, P., & Gonjari, I. (2019). Design and evaluation of sustained-release matrix tablets: A review. International Journal of Pharmaceutical Sciences Review and Research, 59(1), 34–40.
62. Dunne, A., & Corrigan, O. I. (2006). Biopharmaceutical characterization of repaglinide. European Journal of Pharmaceutical Sciences, 28(3), 257–264.
63. Hatorp, V. (2002). Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics, 41(7), 471–483.
64. Chien, Y. W. (1992). Novel drug delivery systems (2nd ed.). Marcel Dekker.
65. Lade, S., Kendre, P., & Gonjari, I. (2019). Design and evaluation of sustained-release matrix tablets: A review. International Journal of Pharmaceutical Sciences Review and Research, 59(1), 34–40.
66. Ravi, P. R., & Siddaramaiah, H. (2010). Design and evaluation of sustained-release matrix tablets of repaglinide. Indian Journal of Pharmaceutical Sciences, 72(2), 253–258.
67. Chien, Y. W. (1992). Novel drug delivery systems (2nd ed.). Marcel Dekker.
68. Kumar, V., Abbas, A. K., & Ahuja, S. (2018). Advances in polymeric drug delivery systems for controlled release. International Journal of Pharmaceutical Sciences and Research, 9(6), 2231–2245.
69. Langer, R. (2000). Biomaterials in drug delivery and tissue engineering. Science, 293(5527), 58–59. https://doi.org/10.1126/science.287.5454.883
70. Prajapati, V. D., Jani, G. K., Moradiya, N. G., & Randeria, N. P. (2013). Floating matrix tablets: Design and evaluation. Journal of Controlled Release, 168(2), 151–165.
71. Thakkar, R., Pillai, A., & Ashour, E. A. (2020). 3D printing in pharmaceutical and biomedical applications. Drug Development and Industrial Pharmacy, 46(2), 201–216. https://doi.org/10.1080/03639045.2019.1708344